Onxeo Overview

  • Founded
  • 1997

Founded
  • Status
  • Public

  • Employees
  • 25

Employees
  • Stock Symbol
  • ALONX

Stock Symbol
  • Investments
  • 3

  • Share Price
  • $0.34

  • (As of Wednesday Closing)

Onxeo General Information

Description

Onxeo SA is a biotechnology company that is engaged in developing oncology drugs based on tumor DNA targeting. The company focuses on developing disruptive compounds from preclinical research. The company's portfolio includes AsiDNA, PlatOn and many more.

Contact Information

Website
www.onxeo.com
Formerly Known As
BioAlliance Pharma
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
PAR
Primary Office
  • 49 Boulevard du General
  • Martial Valin
  • 75015 Paris
  • France
+33 01 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Onxeo Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.34 $0.34 $0.32 - $0.72 $31.4M 91.6M 29.2K -$0.08

Onxeo Financials Summary

In Thousands,
USD
TTM 31-Dec-2021 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 27,038 27,038 50,328 38,941
Revenue 4,802 4,802 2,024 4,800
EBITDA (5,288) (5,288) 3,902 (10,794)
Net Income (7,019) (7,019) 1,241 (37,757)
Total Assets 60,079 60,079 57,201 42,151
Total Debt 16,716 16,716 7,696 9,613
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Onxeo Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Onxeo‘s full profile, request access.

Request a free trial

Onxeo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Onxeo SA is a biotechnology company that is engaged in developing oncology drugs based on tumor DNA targeting. The compa
Drug Discovery
Paris, France
25 As of 2021
00000
000000000 00000

000000

rem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
000000000000000
Loos, France
000 As of 0000
00000
000000000. 0 00000

000000

illum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000000000000
Illkirch-Graffenstaden, France
000 As of 0000
00000
0000 0000-00-00
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Onxeo Competitors (58)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Genfit Formerly VC-backed Loos, France 000 00000 000000000. 0 00000
000000000 Corporation Illkirch-Graffenstaden, France 000 00000 000000000 00000
00000000 000000 Corporation Hellerup, Denmark 000 00000 000000000 00000
000000 000000 Formerly VC-backed Marseille, France 000 00000 000000000 00000
00000000 000000 Corporation Tokyo, Japan 00000 000000&0
You’re viewing 5 of 58 competitors. Get the full list »

Onxeo Patents

Onxeo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020242287-A1 A dbait molecule in combination with kinase inhibitor for the treatment of cancer Pending 21-Mar-2019 00000000000
US-20220143049-A1 A dbait molecule in combination with kinase inhibitor for the treatment of cancer Pending 21-Mar-2019 0000000000
JP-2022526713-A Dbait molecule in combination with a kinase inhibitor for the treatment of cancer Pending 21-Mar-2019 0000000000
EP-3942045-A1 A dbait molecule in combination with kinase inhibitor for the treatment of cancer Pending 21-Mar-2019 00000000000
CA-3129665-A1 A dbait molecule in combination with kinase inhibitor for the treatment of cancer Pending 21-Mar-2019 A61K31/6615
To view Onxeo’s complete patent history, request access »

Onxeo Executive Team (10)

Name Title Board Seat Contact Info
Judith Greciet Ph.D Executive Director & Chief Executive Officer
Nicolas Fellmann Chief Financial Officer & Board Member
Philippe Maitre Chief Operating Officer, Executive Vice President & Head-Business Development & US Division
Michel Forest Chief Pharmacist and Quality Assurance Director
Nicolas Trebouta MD Director of the Board
You’re viewing 5 of 10 executive team members. Get the full list »

Onxeo Board Members (13)

Name Representing Role Since
Andre Ulmann Ph.D Self Member, Supervisory Board 000 0000
Danièle Guyot Caparros Self Chairwoman of the Board 000 0000
Jean-Pierre Bizzari MD Self Independent Director 000 0000
Nicolas Fellmann Onxeo Chief Financial Officer & Board Member 000 0000
Russell Greig Ph.D Kurma Partners Independent Director 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Onxeo Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Onxeo Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Onxeo‘s full profile, request access.

Request a free trial

Onxeo Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 25-Mar-2016 0000000000 00.000 Drug Discovery 000000 00
0000000000 05-Aug-2014 0000000000 00000 Drug Discovery
SpeBio Joint Venture Distributors/Wholesale
To view Onxeo’s complete investments and acquisitions history, request access »

Onxeo Subsidiaries (1)

Company Name Industry Location Founded
0000000000 Drug Discovery Copenhagen, Denmark 0000
To view Onxeo’s complete subsidiaries history, request access »

Onxeo Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000 0000000 Completed
  • 2 buyers
To view Onxeo’s complete exits history, request access »